Advertisement

Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma

  • Grace EganEmail author
  • Sheila Weitzman
  • Sarah Alexander
Chapter

Abstract

Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) are the two most common subtypes of mature B-cell lymphoma seen in childhood. They account for 50–60% of pediatric NHL. Despite differences in biology, childhood BL and DLBCL are treated similarly. Dramatic improvements in outcomes have been made over the past 60 years as a result of sequential cooperative trials administering multi-agent, risk-adapted chemotherapy. The inclusion of immunotherapy in recent trials has further improved outcomes. Despite an overall survival greater than 90% for all patients, short-term toxicity remains substantial with current intensive regimens and outcomes for those with relapsed disease remain poor. Recent advances in molecular and genetic diagnostics offer the opportunity to define and classify disease more accurately. This improved understanding of disease biology enables the development and application of targeted therapies, potentially allowing for substitution of cytotoxic therapy by more specific, less toxic agents, as well as improvement of outcomes for those with refractory disease. Future well-designed collaborative trials are vital to build upon the successes made in the treatment of children with mature B-NHL.

Keywords

Children Mature B-cell lymphoma Burkitt lymphoma Diffuse large B-cell lymphoma DLBCL Management Rituximab 

References

  1. 1.
    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89(11):3909–18.Google Scholar
  2. 2.
    Allday MJ. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt’s lymphoma? Semin Cancer Biol. 2009;19(6):366–76.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Anderson JR, Jenkin RD, Wilson JF, Kjeldsberg CR, Sposto R, Chilcote RR, Coccia PF, Exelby PR, Siegel S, Meadows AT, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin’s lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol. 1993;11(6):1024–32.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Anderson JR, Wilson JF, Jenkin DT, Meadows AT, Kersey J, Chilcote RR, Coccia P, Exelby P, Kushner J, Siegel S, Hammond D. Childhood non-Hodgkin’s lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med. 1983;308(10):559–65.PubMedCrossRefGoogle Scholar
  5. 5.
    Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31(33):4199–206.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Attarbaschi A, Carraro E, Abla O, Barzilai-Birenboim S, Bomken S, Brugieres L, Bubanska E, Burkhardt B, Chiang AK, Csoka M, Fedorova A, Jazbec J, Kabickova E, Krenova Z, Lazic J, Loeffen J, Mann G, Niggli F, Miakova N, Osumi T, Ronceray L, Uyttebroeck A, Williams D, Woessmann W, Wrobel G, Pillon M. Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica. 2016;101(12):1581–91.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Awasthi A, Ayello J, Van de Ven C, Elmacken M, Sabulski A, Barth MJ, Czuczman MS, Islam H, Klein C, Cairo MS. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20+BL and pre-B-ALL. Br J Haematol. 2015;171(5):763–75.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Ayers LW, Tumwine LK. Burkitt’s lymphoma. New York: Springer; 2013.Google Scholar
  9. 9.
    Bhojwani D, McCarville MB, Choi JK, Sawyer J, Metzger ML, Inaba H, Davidoff AM, Gold R, Shulkin BL, Sandlund JT. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. Br J Haematol. 2015;168(6):845–53.CrossRefGoogle Scholar
  10. 10.
    Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, Riehm H, Schrappe M, Reiter A. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131(1):39–49.CrossRefGoogle Scholar
  11. 11.
    Burkitt D. Long-term remissions following one and two-dose chemotherapy for African lymphoma. Cancer. 1967;20(5):756–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Burkitt DP. The discovery of Burkitt’s lymphoma. Cancer. 1983;51(10):1777–86.PubMedCrossRefGoogle Scholar
  13. 13.
    Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, Weston C, Perkins SL, Raphael M, McCarthy K, Patte C, FAB LMB96 International Study Committee. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736–43.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Cairo MS, Shen V, Krailo MD, Bauer M, Miser JS, Sato JK, Blatt J, Blazar BR, Frierdich S, Liu-Mares W, Reaman GH. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children’s cancer group report. J Pediatr Hematol Oncol. 2001;23(1):30–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, Pinkerton R, Raphael M, McCarthy K, Perkins SL, Patte C. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30(4):387–93.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–44.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, June CH, Schuster SJ. PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR. Blood. 2017;129(8):1039–41.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Chu PG, Chang KL, Arber DA, Weiss LM. Practical applications of immunohistochemistry in hematolymphoid neoplasms. Ann Diagn Pathol. 1999;3(2):104–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982;79(24):7824–7.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431–42.CrossRefGoogle Scholar
  22. 22.
    Deffenbacher KE, Iqbal J, Sanger W, Shen Y, Lachel C, Liu Z, Liu Y, Lim MS, Perkins SL, Fu K, Smith L, Lynch J, Staudt LM, Rimsza LM, Jaffe E, Rosenwald A, Ott GK, Delabie J, Campo E, Gascoyne RD, Cairo MS, Weisenburger DD, Greiner TC, Gross TG, Chan WC. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood. 2012;119(16):3757–66.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    El-Mallawany NK, Cairo MS. Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2015;13(2):113–23.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Fowler N, Davis E. Targeting B-cell receptor signaling: changing the paradigm. Hematology Am Soc Hematol Educ Program. 2013;2013:553–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Frost M, Newell J, Lones MA, Tripp SR, Cairo MS, Perkins SL. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol. 2004;121(3):384–92.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Gadner H, Muller-Weihrich S, Riehm H. Treatment strategies in malignant non-Hodgkin lymphomas in childhood. Onkologie. 1986;9(2):126–30.PubMedGoogle Scholar
  27. 27.
    Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, Lambilliote A, Sposto R, McCarthy K, Lacombe MJ, Perkins SL, Patte C. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141(6):840–7.CrossRefGoogle Scholar
  28. 28.
    Gibson TM, Engels EA, Clarke CA, Lynch CF, Weisenburger DD, Morton LM. Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States. Am J Hematol. 2014;89(7):714–20.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Giulino-Roth L, Goldman S. Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children. Br J Haematol. 2016;173(4):531–44.PubMedCrossRefGoogle Scholar
  30. 30.
    Giulino-Roth L, Wang K, MacDonald TY, Mathew S, Tam Y, Cronin MT, Palmer G, Lucena-Silva N, Pedrosa F, Pedrosa M, Teruya-Feldstein J, Bhagat G, Alobeid B, Leoncini L, Bellan C, Rogena E, Pinkney KA, Rubin MA, Ribeiro RC, Yelensky R, Tam W, Stephens PJ, Cesarman E. Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood. 2012;120(26):5181–4.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Goebeler M-E, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S, Mackensen A, Rupertus K, Kanz L, Libicher M, Nagorsen D, Zugmaier G, Klinger M, Wolf A, Dorsch B, Quednau BD, Schmidt M, Scheele J, Baeuerle PA, Leo E, Bargou RC. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;34(10):1104–11.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Goldman S, Barth MJ, Oesterheld JE, Heym K, Harrison L, Nickerson B, El-Mallawany N, Hochberg J, Cairo MS. Preliminary results of a reduced burden of therapy trial by incorporation of rituximab and intrathecal liposomal cytarabine in children, adolescents and young adults with intermediate (FAB Group B) and high risk (FAB Group C) mature B-cell lymphoma/leukemia. J Clin Oncol. 2016;34(15_suppl):10534.CrossRefGoogle Scholar
  33. 33.
    Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo MS. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. Leukemia. 2013;27(5):1174–7.CrossRefGoogle Scholar
  34. 34.
    Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology Group Report. Br J Haematol. 2014;167(3):394–401.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, Shiramizu B, Wiley J, Woods D, Barnich M, Gross TG. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2009;52(2):177–81.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, Hayashi RJ, Termuhlen AM, Zhang MJ, Davies SM, Eapen M. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010;16(2):223–30.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361–92.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kuhn M, Lenze D, Lichter P, Martin-Subero JI, Moller P, Muller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Sturzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH, Spang R, Loeffler M, Trumper L, Stein H, Siebert R. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419–30.CrossRefGoogle Scholar
  39. 39.
    Jourdain A, Auperin A, Minard-Colin V, Aladjidi N, Zsiros J, Coze C, Gandemer V, Bertrand Y, Leverger G, Bergeron C, Michon J, Patte C. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Societe Francaise des Cancers de l’Enfant study. Haematologica. 2015;100(6):810–7.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Kersey JH, Shapiro RS, Filipovich AH. Relationship of immunodeficiency to lymphoid malignancy. Pediatr Infect Dis J. 1988;7(5 Suppl):S10–2.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, Hummel M, Loeffler M, Pellissery S, Woessmann W, Schwanen C, Trumper L, Wessendorf S, Spang R, Hasenclever D, Siebert R. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood. 2012;119(8):1882–7.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Klapper W, Szczepanowski M, Burkhardt B, Berger H, Rosolowski M, Bentink S, Schwaenen C, Wessendorf S, Spang R, Moller P, Hansmann ML, Bernd HW, Ott G, Hummel M, Stein H, Loeffler M, Trumper L, Zimmermann M, Reiter A, Siebert R. Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood. 2008;112(4):1374–81.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Kung FH, Harris MB, Krischer JP. Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a Pediatric Oncology Group phase II study. Med Pediatr Oncol. 1999;32(3):225–6.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Ladenstein R, Pearce R, Hartmann O, Patte C, Goldstone T, Philip T. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt’s lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood. 1997;90(8):2921–30.PubMedPubMedCentralGoogle Scholar
  46. 46.
    LaQuaglia MP, Stolar CJ, Krailo M, Exelby P, Siegel S, Meadows A, Hammond D. The role of surgery in abdominal non-Hodgkin’s lymphoma: experience from the Childrens Cancer Study Group. J Pediatr Surg. 1992;27(2):230–5.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Lenze D, Leoncini L, Hummel M, Volinia S, Liu CG, Amato T, De Falco G, Githanga J, Horn H, Nyagol J, Ott G, Palatini J, Pfreundschuh M, Rogena E, Rosenwald A, Siebert R, Croce CM, Stein H. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia. 2011;25(12):1869–76.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy SB. Results of treatment of childhood localized non-Hodgkin’s lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med. 1990;322(17):1169–74.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44(12):1321–5.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol. 2012a;156(6):744–56.CrossRefGoogle Scholar
  51. 51.
    Magrath I. Towards curative therapy in Burkitt lymphoma: the role of early African studies in demonstrating the value of combination therapy and CNS prophylaxis. Adv Hematol. 2012b;2012:130680.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Magrath IT, Lwanga S, Carswell W, Harrison N. Surgical reduction of tumour bulk in management of abdominal Burkitt’s lymphoma. Br Med J. 1974;2(5914):308–12.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Mann RB, Jaffe ES, Braylan RC, Nanba K, Frank MM, Ziegler JL, Berard CW. Non-endemic Burkitts’s lymphoma. A B-cell tumor related to germinal centers. N Engl J Med. 1976;295(13):685–91.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Masque-Soler N, Szczepanowski M, Kohler CW, Aukema SM, Nagel I, Richter J, Siebert R, Spang R, Burkhardt B, Klapper W. Clinical and pathological features of Burkitt lymphoma showing expression of BCL2--an analysis including gene expression in formalin-fixed paraffin-embedded tissue. Br J Haematol. 2015;171(4):501–8.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper W, Attarbaschi A, Schrappe M, Reiter A. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. J Clin Oncol. 2010;28(19):3115–21.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, Patte C, Gerrard M, Auperin A, Sposto R, Davenport V, Cairo MS, Perkins SL. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) international study group. Pediatr Blood Cancer. 2008;51(3):369–74.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Minard-Colin V, Auperin A, Pillon M, Burke A, Anderson JR, Barkauskas DA, Wheatley K, Delgado R, Alexander S, Uyttebroeck A, Bollard C, Zsiros J, Csoka M, Goma G, Tulard A, Patte C, Gross TG. Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. J Clin Oncol. 2016;34(15_suppl):10507.CrossRefGoogle Scholar
  59. 59.
    Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S. Burkitt’s lymphoma. Lancet. 2012;379(9822):1234–44.CrossRefGoogle Scholar
  60. 60.
    Morrow RH, Pike MC, Kisuule A. Survival of Burkitt’s lymphoma patients in Mulago Hospital, Uganda. Br Med J. 1967;4(5575):323–7.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Murphy SB, Hustu HO. A randomized trial of combined modality therapy of childhood non-Hodgkin’s lymphoma. Cancer. 1980;45(4):630–7.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Mussolin L, Pillon M, Conter V, Piglione M, Lo Nigro L, Pierani P, Micalizzi C, Buffardi S, Basso G, Zanesco L, Rosolen A. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood. J Clin Oncol. 2007;25(33):5254–61.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Mussolin L, Pillon M, d’Amore ES, Conter V, Piglione M, Lo Nigro L, Garaventa A, Buffardi S, Arico M, Rosolen A. Minimal disseminated disease in high-risk Burkitt’s lymphoma identifies patients with different prognosis. J Clin Oncol. 2011;29(13):1779–84.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma. 2009;50(6):886–91.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Ngu VA. Chemotherapy of Burkitt’s tumor at the University of Ibadan, Nigeria. JAMA. 1972;222(9):1166.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Nkrumah FK, Perkins IV, Biggar RJ. Combination chemotherapy in abdominal Burkitt’s lymphoma. Cancer. 1977;40(4):1410–6.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Norin T, Onyango J. Radiotherapy in Burkitt’s lymphoma conventional or superfractionated regime—early results. Int J Radiat Oncol Biol Phys. 1977;2(5):399–406.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Oettgen HF, Burkitt D, Burchenal JH. Malignant lymphoma involving the jaw in African children: treatment with Methotrexate. Cancer. 1963a;16:616–23.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Oettgen HF, Clifford P, Burkitt D. Malignant lymphoma involving the jaw in African children: treatment with alkylating agents and actinomycin D. Cancer Chemother Rep. 1963b;28:25–34.PubMedGoogle Scholar
  71. 71.
    Olweny CL, Atine I, Kaddu-Mukasa A, Katongole-Mbidde E, Lwanga SK, Johansson B, Onyango J, Host H, Norin T, Willey B. Cerebrospinal irradiation of Burkitt’s lymphoma. Failure in preventing central nervous system relapse. Acta Radiol Ther Phys Biol. 1977;16(3):225–31.PubMedCrossRefGoogle Scholar
  72. 72.
    Olweny CL, Katongole-Mbidde E, Kaddu-Mukasa A, Atine I, Owor R, Lwanga S, Carswell W, Magrath IT. Treatment of Burkitt’s lymphoma: randomized clinical trial of single-agent versus combination chemotherapy. Int J Cancer. 1976;17(4):436–40.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Olweny CL, Katongole-Mbidde E, Otim D, Lwanga SK, Magrath IT, Ziegler JL. Long-term experience with Burkitt’s lymphoma in Uganda. Int J Cancer. 1980;26(3):261–6.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Onciu M, Schlette E, Zhou Y, Raimondi SC, Giles FJ, Kantarjian HM, Medeiros LJ, Ribeiro RC, Pui CH, Sandlund JT. Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer. 2006;107(5):1084–92.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Oschlies I, Klapper W, Zimmermann M, Krams M, Wacker HH, Burkhardt B, Harder L, Siebert R, Reiter A, Parwaresch R. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood. 2006;107(10):4047–52.Google Scholar
  76. 76.
    Palanca-Wessels MCA, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu Y-W, Morschhauser F. Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704–15.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773–80.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Lutz P, Coze C, Perel Y, Raphael M, Terrier-Lacombe MJ. The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370–9.CrossRefGoogle Scholar
  79. 79.
    Patte C, Gerrard M., Auperin A, et al. (2003). Early treatment intensity has a major prognostic impact in the “intermediate risk” childhood and adolescent B-cell lymphoma: results of the international FAB LMB 96 trial. Abstract of the American Society of Hematology.Google Scholar
  80. 80.
    Patte C, Philip T, Rodary C, Bernard A, Zucker JM, Bernard JL, Robert A, Rialland X, Benz-Lemoine E, Demeocq F, et al. Improved survival rate in children with stage III and IV B cell non-Hodgkin’s lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol. 1986;4(8):1219–26.PubMedCrossRefGoogle Scholar
  81. 81.
    Pelicci PG, Knowles DM 2nd, Magrath I, Dalla-Favera R. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A. 1986;83(9):2984–8.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Percy, C. L., M. A. Smith, M. Linet, L. A. Gloeckler Ries and D. L. Friedman (1999). Lymphomas and reticuloendothelial neoplasms. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program L Ries, MA Smith, JG Gurney et al. National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD, 35–50.Google Scholar
  83. 83.
    Perkins SL. Work-up and diagnosis of pediatric non-Hodgkin’s lymphomas. Pediatr Dev Pathol. 2000;3(4):374–90.CrossRefGoogle Scholar
  84. 84.
    Perkins SL, Lones MA, Davenport V, Cairo MS. B-Cell non-Hodgkin’s lymphoma in children and adolescents: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children’s cancer group report. Clin Adv Hematol Oncol. 2003;1(5):314–7.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Perkins SL, Morris SW. Biology and pathology of pediatric non-Hodgkin lymphoma pediatric lymphomas. H. J. H. Weinstein, M. M.; Link, M. P. Berlin Heidelberg: Springer; 2007.Google Scholar
  86. 86.
    Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–91.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Philip T, Hartmann O, Pinkerton R, Zucker JM, Gentet JC, Lamagnere JP, Berhendt H, Perel Y, Otten J, Lutz P, et al. Curability of relapsed childhood B-cell non-Hodgkin’s lymphoma after intensive first line therapy: a report from the Societe Francaise d’Oncologie Pediatrique. Blood. 1993;81(8):2003–6.PubMedGoogle Scholar
  88. 88.
    Pilecki B, Kopiec P, Zajusz A, Podworski H, Szelc S, Skladowski K, Maciejewski B. Hyperfractionated radiotherapy for Burkitt-type lymphoma. Radiobiological aspects. Neoplasma. 1991;38(6):609–15.PubMedGoogle Scholar
  89. 89.
    Poirel HA, Cairo MS, Heerema NA, Swansbury J, Auperin A, Launay E, Sanger WG, Talley P, Perkins SL, Raphael M, McCarthy K, Sposto R, Gerrard M, Bernheim A, Patte C. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2009;23(2):323–31.PubMedCrossRefGoogle Scholar
  90. 90.
    Rainey JJ, Mwanda WO, Wairiumu P, Moormann AM, Wilson ML, Rochford R. Spatial distribution of Burkitt’s lymphoma in Kenya and association with malaria risk. Trop Med Int Health. 2007;12(8):936–43.PubMedCrossRefGoogle Scholar
  91. 91.
    Ramos CA, Heslop HE, Brenner MK. CAR-T cell therapy for lymphoma. Annu Rev Med. 2016a;67:165–83.PubMedCrossRefGoogle Scholar
  92. 92.
    Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G. Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains. J Clin Invest. 2016b;126(7):2588–96.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Reiter A, Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol. 2008;142(3):329–47.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, Mann G, Chott A, Ebell W, Klingebiel T, Graf N, Kremens B, Muller-Weihrich S, Pluss HJ, Zintl F, Henze G, Riehm H. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94(10):3294–306.Google Scholar
  95. 95.
    Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs. 2011;25(1):13–25.PubMedCrossRefGoogle Scholar
  96. 96.
    Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–47.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Rosolen A, Perkins SL, Pinkerton CR, Guillerman RP, Sandlund JT, Patte C, Reiter A, Cairo MS. Revised international pediatric non-Hodgkin lymphoma staging system. J Clin Oncol. 2015;33(18):2112–8.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Salavoura K, Kolialexi A, Tsangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res. 2008;28(2b):1263–9.PubMedGoogle Scholar
  99. 99.
    Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin’s lymphoma differ by non-Hodgkin’s lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol. 2007;25(25):3915–22.PubMedCrossRefGoogle Scholar
  100. 100.
    Sandlund JT, Bowman L, Heslop HE, Krance R, Mahmoud H, Pui C, Hale G, Benaim E. Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refractory NHL. Cytotherapy. 2002;4(3):253–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Satwani P, Jin Z, Martin PL, Bhatia M, Garvin JH, George D, Chaudhury S, Talano J, Morris E, Harrison L, Sosna J, Peterson M, Militano O, Foley S, Kurtzberg J, Cairo MS. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia. 2015;29(2):448–55.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116–20.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–54.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L, Harrison L, Morris E, Gross TG, Sanger W, Perkins S, Cairo MS. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children’s oncology group report. Br J Haematol. 2011;153(6):758–63.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Shiramizu B, Goldman S, Smith L, Agsalda-Garcia M, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Barth MJ, Mussolin L, Cairo MS. Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children’s Oncology Group Pilot Study Report. Br J Haematol. 2015;170(3):367–71.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: WHO; 2008.Google Scholar
  107. 107.
    Tiwari A, Edani D, Ayello J, Klein C, Lee DA, Cairo MS. Polatuzumab vedotin alone or in combination with obinutuzumab synergistically enhances in-vitro cytotoxicity and cytokine release against CD20+/ CD79b+ Burkitt lymphoma (BL) /primary mediastinal large B cell lymphoma (PMBL). Blood. 2017;130(Suppl 1):1540.Google Scholar
  108. 108.
    Topp MS, Gokbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foa R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Bruggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.PubMedCrossRefGoogle Scholar
  109. 109.
    Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C, Stieglmaier J, Zhang A, Nagorsen D, Bargou RC. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410–6.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Vitolo U, Trneny M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529–37.CrossRefGoogle Scholar
  111. 111.
    von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O’Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu M, Whitlock JA, Gore L. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381–9.CrossRefGoogle Scholar
  112. 112.
    Wilson WH, Gerecitano JF, Goy A, de Vos S, Kenkre VP, Barr PM, Blum KA, Shustov AR, Advani RH, Lih J, Williams M, Schmitz R, Yang Y, Pittaluga S, Wright G, Kunkel LA, McGreivy J, Balasubramanian S, Cheng M, Moussa D, Buggy JJ, Staudt LM. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, Phase 2 study. Blood. 2012;120(21):686.Google Scholar
  113. 113.
    Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005a;105(3):948–58.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A, BFM Group. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005b;105(3):948–58.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15(9):1019–26.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Zhang WY, Wang Y, Guo YL, Dai HR, Yang QM, Zhang YJ, Zhang Y, Chen MX, Wang CM, Feng KC, Li SX, Liu Y, Shi FX, Luo C, Han WD. Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal Transduct Target Ther. 2016;1:16002.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Ziegler JL. Treatment results of 54 American patients with Burkitt’s lymphoma are similar to the African experience. N Engl J Med. 1977;297(2):75–80.PubMedCrossRefGoogle Scholar
  118. 118.
    Ziegler JL, Beckstead JA, Volberding PA, Abrams DI, Levine AM, Lukes RJ, Gill PS, Burkes RL, Meyer PR, Metroka CE, et al. Non-Hodgkin’s lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med. 1984;311(9):565–70.PubMedCrossRefGoogle Scholar
  119. 119.
    Ziegler JL, Bluming AZ, Magrath IT, Carbone PP. Intensive chemotherapy in patients with generalized Burkitt’s lymphoma. Int J Cancer. 1972;10(2):254–61.PubMedCrossRefGoogle Scholar
  120. 120.
    Ziegler JL, Morrow RH Jr, Fass L, Kyalwazi SK, Carbone PP. Treatment of Burkitt’s tumor with cyclophosphamide. Cancer. 1970;26(2):474–84.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Haematology/Oncology, Department of PediatricsThe Hospital for Sick Children, University of TorontoTorontoCanada

Personalised recommendations